Relative resistance of HIV-1 founder viruses to control by interferon-alpha

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Fenton-May, Angharad E
    • Other Affiliation: Nuffield Department of Medicine, University of Oxford
  • Dibben, Oliver
    • Other Affiliation: Nuffield Department of Medicine, University of Oxford
  • Emmerich, Tanja
    • Other Affiliation: Nuffield Department of Medicine, University of Oxford
  • Ding, Haitao
    • Other Affiliation: Department of Medicine, University of Alabama at Birmingham
  • Pfafferott, Katja
    • Other Affiliation: Nuffield Department of Medicine, University of Oxford
  • Aasa-Chapman, Marlen M
    • Other Affiliation: Division of Infection and Immunity, Faculty of Medicine and Centre for Sexual Health & HIV Research
  • Pellegrino, Pierre
    • Other Affiliation: Centre for Sexual Health & HIV Research, Mortimer Market Centre, University College London
  • Williams, Ian
    • Other Affiliation: Centre for Sexual Health & HIV Research, Mortimer Market Centre, University College London
  • Cohen, Myron
    • Affiliation: School of Medicine, Department of Medicine
  • Gao, Feng
    • Other Affiliation: Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Centre
  • Shaw, George M
    • Other Affiliation: Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
  • Hahn, Beatrice H
    • Other Affiliation: Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
  • Ochsenbauer, Christina
    • Other Affiliation: Department of Medicine, University of Alabama at Birmingham
  • Kappes, John C
    • Other Affiliation: Department of Medicine, University of Alabama at Birmingham
  • Borrow, Persephone
    • Other Affiliation: Nuffield Department of Medicine, University of Oxford
Abstract
  • Background: Following mucosal human immunodeficiency virus type 1 (HIV-1) transmission, type 1 interferons (IFNs) are rapidly induced at sites of initial virus replication in the mucosa and draining lymph nodes. However, the role played by IFN-stimulated antiviral activity in restricting HIV-1 replication during the initial stages of infection is not clear. We hypothesized that if type 1 IFNs exert selective pressure on HIV-1 replication in the earliest stages of infection, the founder viruses that succeed in establishing systemic infection would be more IFN-resistant than viruses replicating during chronic infection, when type 1 IFNs are produced at much lower levels. To address this hypothesis, the relative resistance of virus isolates derived from HIV-1-infected individuals during acute and chronic infection to control by type 1 IFNs was analysed. Results: The replication of plasma virus isolates generated from subjects acutely infected with HIV-1 and molecularly cloned founder HIV-1 strains could be reduced but not fully suppressed by type 1 IFNs in vitro. The mean IC50 value for IFNα2 (22 U/ml) was lower than that for IFNβ (346 U/ml), although at maximally-inhibitory concentrations both IFN subtypes inhibited virus replication to similar extents. Individual virus isolates exhibited differential susceptibility to inhibition by IFNα2 and IFNβ, likely reflecting variation in resistance to differentially up-regulated IFN-stimulated genes. Virus isolates from subjects acutely infected with HIV-1 were significantly more resistant to in vitro control by IFNα than virus isolates generated from the same individuals during chronic, asymptomatic infection. Viral IFN resistance declined rapidly after the acute phase of infection: in five subjects, viruses derived from six-month consensus molecular clones were significantly more sensitive to the antiviral effects of IFNs than the corresponding founder viruses. Conclusions: The establishment of systemic HIV-1 infection by relatively IFNα-resistant founder viruses lends strong support to the hypothesis that IFNα plays an important role in the control of HIV-1 replication during the earliest stages of infection, prior to systemic viral spread. These findings suggest that it may be possible to harness the antiviral activity of type 1 IFNs in prophylactic and potentially also therapeutic strategies to combat HIV-1 infection.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Angharad E Fenton-May et al.; licensee BioMed Central Ltd.
License
Journal title
  • Retrovirology
Journal volume
  • 10
Journal issue
  • 1
Page start
  • 146
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1742-4690
Bibliographic citation
  • Retrovirology. 2013 Dec 03;10(1):146
Publisher
  • BioMed Central Ltd
Access right
  • Open Access
Date uploaded
  • December 11, 2013

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 1742-4690-10-146.pdf 2019-05-06 Public Download
file details 1742-4690-10-146.xml 2019-05-06 Public Download